BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Piran S, Khatib R, Schulman S, Majeed A, Holbrook A, Witt DM, Wiercioch W, Schünemann HJ, Nieuwlaat R. Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. Blood Adv 2019;3:158-67. [PMID: 30658963 DOI: 10.1182/bloodadvances.2018024133] [Cited by in Crossref: 59] [Cited by in F6Publishing: 46] [Article Influence: 29.5] [Reference Citation Analysis]
Number Citing Articles
1 Curry B, Mueller S, MacLaren R. The Use of Prothrombin Complex Concentrates: Results of a Nationwide Survey of Critical Care Pharmacists. J Pharm Pract 2022;35:197-204. [PMID: 35484869 DOI: 10.1177/0897190020966184] [Reference Citation Analysis]
2 Ngu S, Smith JK, Goldin M. Use of Anticoagulants in COVID-19: A Review. Am J Ther 2022. [PMID: 35476050 DOI: 10.1097/MJT.0000000000001515] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lukas JG, Reichert MJ, Jones GM. Use of Prothrombin Complex Concentrate in Oral Anticoagulant-Associated Major Bleeding. Crit Care Nurs Q 2022;45:167-79. [PMID: 35212656 DOI: 10.1097/CNQ.0000000000000399] [Reference Citation Analysis]
4 Stubbs DJ, Davies B, Hutchinson P, Menon DK; Improving Care in Elderly Neurosurgery Initiative (ICENI). Challenges and opportunities in the care of chronic subdural haematoma: perspectives from a multi-disciplinary working group on the need for change. Br J Neurosurg 2022;:1-9. [PMID: 35089847 DOI: 10.1080/02688697.2021.2024508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yen CC, Wang CK, Chaou CH, Chen SY, Lin JP, Ng CJ. Anticoagulant Therapy Is Associated With Decreased Long-Term Mortality in Splenic Infarction Patients: A Multicenter Study. Front Med (Lausanne) 2021;8:778198. [PMID: 34912831 DOI: 10.3389/fmed.2021.778198] [Reference Citation Analysis]
6 Huttner HB, Gerner ST, Kuramatsu JB, Connolly SJ, Beyer-Westendorf J, Demchuk AM, Middeldorp S, Zotova E, Altevers J, Andersohn F, Christoph MJ, Yue P, Stross L, Schwab S. Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care. Stroke 2021;:STROKEAHA121034572. [PMID: 34645283 DOI: 10.1161/STROKEAHA.121.034572] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
7 Ghosh S, Krege W, Doerr B, Mischnik M, Pragst I, Dickneite G, Herzog E. Evaluation of the prothrombotic potential of four-factor prothrombin complex concentrate (4F-PCC) in animal models. PLoS One 2021;16:e0258192. [PMID: 34614035 DOI: 10.1371/journal.pone.0258192] [Reference Citation Analysis]
8 Stevens VM, Trujillo TC, Kiser TH, MacLaren R, Reynolds PM, Mueller SW. Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding. Clin Appl Thromb Hemost 2021;27:10760296211039020. [PMID: 34541920 DOI: 10.1177/10760296211039020] [Reference Citation Analysis]
9 Smythe MA, Koerber JM, Hoffman JL, Mertz S, Fritsch K, Chehab F, Baalbaki N, Krishnan A. Outcomes of activated prothrombin complex concentrate for direct Xa inhibitor bleeding. Thromb Res 2021;206:142-4. [PMID: 34481221 DOI: 10.1016/j.thromres.2021.08.011] [Reference Citation Analysis]
10 Veitch AM, Radaelli F, Alikhan R, Dumonceau JM, Eaton D, Jerrome J, Lester W, Nylander D, Thoufeeq M, Vanbiervliet G, Wilkinson JR, Van Hooft JE. Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. Gut 2021;70:1611-28. [PMID: 34362780 DOI: 10.1136/gutjnl-2021-325184] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
11 Rayatdoost F, Braunschweig T, Maron B, Schöchl H, Akman N, Rossaint R, Herzog E, Heitmeier S, Grottke O. Reversing Rivaroxaban Anticoagulation as Part of a Multimodal Hemostatic Intervention in a Polytrauma Animal Model. Anesthesiology 2021. [PMID: 34370811 DOI: 10.1097/ALN.0000000000003899] [Reference Citation Analysis]
12 Veitch AM, Radaelli F, Alikhan R, Dumonceau JM, Eaton D, Jerrome J, Lester W, Nylander D, Thoufeeq M, Vanbiervliet G, Wilkinson JR, van Hooft JE. Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. Endoscopy 2021;53:947-69. [PMID: 34359080 DOI: 10.1055/a-1547-2282] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 11.0] [Reference Citation Analysis]
13 Shmookler AD, Nichols TL, Perrotta PL. A Tertiary Academic Medical Center Blood Bank's Experience With Four-Factor Prothrombin Complex Concentrate. Am J Clin Pathol 2021;156:246-52. [PMID: 33609094 DOI: 10.1093/ajcp/aqaa226] [Reference Citation Analysis]
14 Procopio GL, Jain RP, Tompkins DM, Perez JM, Bicking K. Impact of a pharmacist driven anticoagulation reversal program at a large academic medical center. J Thromb Thrombolysis 2021. [PMID: 34097227 DOI: 10.1007/s11239-021-02491-7] [Reference Citation Analysis]
15 Hafer A, McCann L. Direct oral anticoagulant reversal: An update. Nursing 2021;51:54-64. [PMID: 34014879 DOI: 10.1097/01.NURSE.0000743104.69943.67] [Reference Citation Analysis]
16 Triantafyllou K, Gkolfakis P, Gralnek IM, Oakland K, Manes G, Radaelli F, Awadie H, Camus Duboc M, Christodoulou D, Fedorov E, Guy RJ, Hollenbach M, Ibrahim M, Neeman Z, Regge D, Rodriguez de Santiago E, Tham TC, Thelin-Schmidt P, van Hooft JE. Diagnosis and management of acute lower gastrointestinal bleeding: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2021;53:850-68. [PMID: 34062566 DOI: 10.1055/a-1496-8969] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 21.0] [Reference Citation Analysis]
17 Gómez-Outes A, Alcubilla P, Calvo-Rojas G, Terleira-Fernández AI, Suárez-Gea ML, Lecumberri R, Vargas-Castrillón E. Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants. J Am Coll Cardiol 2021;77:2987-3001. [PMID: 34140101 DOI: 10.1016/j.jacc.2021.04.061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Jaspers T, Shudofsky K, Huisman MV, Meijer K, Khorsand N. A meta-analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor-related major bleeding. Res Pract Thromb Haemost 2021;5:e12518. [PMID: 34084991 DOI: 10.1002/rth2.12518] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
19 Milioglou I, Farmakis I, Neudeker M, Hussain Z, Guha A, Giannakoulas G, Kotoula V, Papaioannou M. Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis. J Thromb Thrombolysis 2021. [PMID: 34024021 DOI: 10.1007/s11239-021-02480-w] [Reference Citation Analysis]
20 Khorsand N, Beyer-Westendorf J, Sarode R, Schulman S, Meijer K. Definition of haemostatic effectiveness in interventions used to treat major bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost 2021;19:1112-5. [PMID: 33792175 DOI: 10.1111/jth.15222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Galhardo C Jr, Yamauchi LHI, Dantas H, Guerra JCC. Clinical protocols for oral anticoagulant reversal during high risk of bleeding for emergency surgical and nonsurgical settings: a narrative review. Braz J Anesthesiol 2021;71:429-42. [PMID: 33887335 DOI: 10.1016/j.bjane.2021.03.007] [Reference Citation Analysis]
22 Peck KA, Ley EJ, Brown CV, Moore EE, Sava JA, Ciesla DJ, Sperry JL, Rizzo AG, Rosen NG, Brasel KJ, Kozar R, Inaba K, Martin MJ. Early anticoagulant reversal after trauma: A Western Trauma Association critical decisions algorithm. J Trauma Acute Care Surg 2021;90:331-6. [PMID: 33055578 DOI: 10.1097/TA.0000000000002979] [Reference Citation Analysis]
23 Siegal DM. Ciraparantag: the next anticoagulant airbag? Blood 2021;137:10-1. [PMID: 33410903 DOI: 10.1182/blood.2020008801] [Reference Citation Analysis]
24 Charlesworth M, Hayes T, Erdoes G. Reversal Agents for the Management of Direct Oral Anticoagulant-Related Bleeding in Cardiac Surgical Patients: The Emperor's New Clothes? J Cardiothorac Vasc Anesth 2021;35:2480-2. [PMID: 33985882 DOI: 10.1053/j.jvca.2021.04.007] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
25 Rech MA, Masic D, Hammond DA. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding. West J Emerg Med 2021;22:163-9. [PMID: 33856296 DOI: 10.5811/westjem.2020.11.47931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Chan N, Sobieraj-Teague M, Eikelboom JW. Direct oral anticoagulants: evidence and unresolved issues. Lancet 2020;396:1767-76. [PMID: 33248499 DOI: 10.1016/S0140-6736(20)32439-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
27 Condeni MS, Basting AT, Costello PG, DePriest A, Eriksson EA, Evans H, Hertel K, Holder AL, Kester AN, Kowalski KR, Bell CM, McLean B, Reichert M, Santibañez M, Wieruszewski PM, Newsome AS. Major publications in the critical care pharmacotherapy literature: 2019. J Crit Care 2021;62:197-205. [PMID: 33422810 DOI: 10.1016/j.jcrc.2020.12.018] [Reference Citation Analysis]
28 Frank AK, Ganesan P, Thompson A, Fang MC. Use and outcomes of prothrombin complex concentrate for factor Xa inhibitor-associated bleeding. Thromb Res 2021;198:132-4. [PMID: 33326909 DOI: 10.1016/j.thromres.2020.11.037] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Lipari L, Yang S, Milligan B, Blunck J. Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate. The American Journal of Emergency Medicine 2020;38:2641-5. [DOI: 10.1016/j.ajem.2020.08.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Highsmith EA, Morton C, Varnado S, Donahue KR, Sulhan S, Lista A. Outcomes Associated With 4-Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients. J Clin Pharmacol 2021;61:598-605. [PMID: 33094836 DOI: 10.1002/jcph.1779] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Bavalia R, Abdoellakhan R, Beenen LF, Brekelmans MPA, Olie RH, Ten Cate H, Huisman MV, Kruip M, Middeldorp S, Meijer K, Hutten BA, Coppens M. Outcome of intracranial bleeding managed with prothrombin complex concentrate in patients on direct factor Xa inhibitors or vitamin K antagonists. Thromb Res 2020;196:404-9. [PMID: 33011638 DOI: 10.1016/j.thromres.2020.09.028] [Reference Citation Analysis]
32 Rodríguez JI, Kobus V, Téllez I, Pérez G. Prophylaxis with rivaroxaban after laparoscopic sleeve gastrectomy could reduce the frequency of portomesenteric venous thrombosis. Ann R Coll Surg Engl 2020;102:712-6. [PMID: 32969260 DOI: 10.1308/rcsann.2020.0209] [Reference Citation Analysis]
33 Lindhoff-Last E, Herrmann E, Lindau S, Konstantinides S, Grottke O, Nowak-Goettl U, Lucks J, Zydek B, Heymann CV, Birschmann I, Sümnig A, Beyer-Westendorf J, Schellong S, Meybohm P, Greinacher A. Severe Hemorrhage Associated With Oral Anticoagulants. Dtsch Arztebl Int 2020;117:312-9. [PMID: 32605708 DOI: 10.3238/arztebl.2020.0312] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
34 Milling TJ, Pollack CV. A review of guidelines on anticoagulation reversal across different clinical scenarios – Is there a general consensus? The American Journal of Emergency Medicine 2020;38:1890-903. [DOI: 10.1016/j.ajem.2020.05.086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
35 Lu G, Lin J, Bui K, Curnutte JT, Conley PB. Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation. Res Pract Thromb Haemost 2020;4:1282-94. [PMID: 33313467 DOI: 10.1002/rth2.12418] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
36 Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Gluckman TJ, Hucker WJ, Mehran R, Messé SR, Perino AC, Rodriguez F, Sarode R, Siegal DM, Wiggins BS. 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. Journal of the American College of Cardiology 2020;76:594-622. [DOI: 10.1016/j.jacc.2020.04.053] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 19.0] [Reference Citation Analysis]
37 Crawley RM, Anderson RL. Prevention and Treatment of Bleeding with Direct Oral Anticoagulants. Drugs 2020;80:1293-308. [PMID: 32691292 DOI: 10.1007/s40265-020-01345-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
38 Erdoes G, Koster A, Ortmann E, Meesters MI, Bolliger D, Baryshnikova E, Martinez Lopez De Arroyabe B, Ahmed A, Lance MD, Ranucci M, von Heymann C, Agarwal S, Ravn HB. A European consensus statement on the use of four-factor prothrombin complex concentrate for cardiac and non-cardiac surgical patients. Anaesthesia 2021;76:381-92. [PMID: 32681570 DOI: 10.1111/anae.15181] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
39 Radaelli F, Fuccio L, Paggi S, Bono CD, Dumonceau JM, Dentali F. What gastroenterologists should know about direct oral anticoagulants. Dig Liver Dis 2020;52:1115-25. [PMID: 32532603 DOI: 10.1016/j.dld.2020.04.032] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
40 Kim C, Cottingham L, Eberwein K, Komyathy K, Ratliff PD. Comparison of Hemostatic Outcomes in Patients Receiving Fixed-Dose vs. Weight-Based 4-Factor Prothrombin Complex Concentrate. J Emerg Med 2020;59:25-32. [PMID: 32536491 DOI: 10.1016/j.jemermed.2020.04.049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Kimpton M, Siegal DM. Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor-associated major bleeding. Hematology Am Soc Hematol Educ Program 2019;2019:204-8. [PMID: 31808849 DOI: 10.1182/hematology.2019000074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Sheikh-Taha M, Crawley RM. Reversal of Apixaban and Rivaroxaban Using Activated Prothrombin Complex Concentrates in Patients with Major Bleeding. Am J Cardiovasc Drugs 2020;20:295-9. [PMID: 31709499 DOI: 10.1007/s40256-019-00383-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
43 Panos NG, Cook AM, John S, Jones GM, Kelly H, Choi RK, Kalaria N, Rosini JM, Jones M, Rehman M, Ross PM, Motley B, Delibert S, George BP, Andrews CM, Neyens RR, Martin R, Schomer KJ, Armahizer MJ, Pajoumand M, May CC, Smetana KS, Strohm T, Hamm C, Jakubowski L, Keegan SP, Srinivasan V, Burdick CJ, Martinez OJ, Bahrassa F, May ST, Sowers KA, Lin EI, Rohaley DJ, Mackey J, Wetmore LL, Frick C, Thatikunta M, Urben L, Ammar AA, Owusu KA, Nguyen K, Erdman MJ, Gilbert BW, Demott JM, Peksa GD, Tobias PE, Da Silva I, Mahmoud LN, Sheahan B, Gennaro AG, Pizzi MA, Brophy GM, Rivet DJ, Strein M, Arandela K, Hellerslia V, Caylor MM. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates. Circulation 2020;141:1681-9. [DOI: 10.1161/circulationaha.120.045769] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 14.0] [Reference Citation Analysis]
44 Barra ME, Das AS, Hayes BD, Rosenthal ES, Rosovsky RP, Fuh L, Patel AB, Goldstein JN, Roberts RJ. Evaluation of andexanet alfa and four‐factor prothrombin complex concentrate (4F‐PCC) for reversal of rivaroxaban‐ and apixaban‐associated intracranial hemorrhages. J Thromb Haemost 2020;18:1637-47. [DOI: 10.1111/jth.14838] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 11.5] [Reference Citation Analysis]
45 Bavalia R, Abdoellakhan R, Brinkman HJM, Brekelmans MPA, Hamulyák EN, Zuurveld M, Hutten BA, Westerweel PE, Olie RH, Ten Cate H, Kruip M, Middeldorp S, Meijer K, Coppens M. Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate. Res Pract Thromb Haemost 2020;4:569-81. [PMID: 32548555 DOI: 10.1002/rth2.12336] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
46 Langer A, Connors JM. Assessing and Reversing the Effect of Direct Oral Anticoagulants on Coagulation. Anesthesiology 2020;133:223-32. [PMID: 32217870 DOI: 10.1097/ALN.0000000000003268] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Levy JH, Connors JM, Steiner ME, Douketis J, Spyropoulos AC. Management of oral anticoagulants prior to emergency surgery or with major bleeding: A survey of perioperative practices in North America: Communication from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis. Res Pract Thromb Haemost 2020;4:562-8. [PMID: 32548554 DOI: 10.1002/rth2.12320] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
48 Noordergraaf FA, Alings M; Department of Cardiology, Amphia Hospital, Breda, Netherlands, Department of Cardiology, Amphia Hospital, Breda, Netherlands, Heart & Lung Division, Utrecht University Medical Center, Utrecht, Netherlands. Andexanet Alfa and its Clinical Application. Heart International 2020;14:20. [DOI: 10.17925/hi.2020.14.1.20] [Reference Citation Analysis]
49 Duong A, Sing S, Taketa C, Miske A, Segal E, Garcia D. Practical considerations for the use of direct oral anticoagulants in oncology patients. J Oncol Pharm Pract 2020;26:692-702. [PMID: 31840565 DOI: 10.1177/1078155219893008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
50 Ratliff P, Nutley K, Schroeder W, Cottingham L. Intraosseous administration of 4‐factor prothrombin complex concentrate prior to emergent surgery after receiving apixaban. J Clin Pharm Ther 2020;45:577-9. [DOI: 10.1111/jcpt.13094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Zada I, Wang S, Akerman M, Hanna A. Four-Factor Prothrombin Complex Concentrate for the Reversal of Direct Oral Anticoagulants. J Intensive Care Med 2021;36:58-62. [PMID: 31746285 DOI: 10.1177/0885066619882909] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
52 Grottke O, Schulman S. Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X Inhibitors. Anesthesiology 2019;131:1153-65. [DOI: 10.1097/aln.0000000000002910] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
53 Abdulrehman J, Eikelboom JW, Siegal DM. Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence. Future Cardiology 2019;15:395-404. [DOI: 10.2217/fca-2019-0038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
54 Frontera JA, Bhatt P, Lalchan R, Yaghi S, Ahuja T, Papadopoulos J, Joset D. Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage. J Thromb Thrombolysis 2020;49:121-31. [DOI: 10.1007/s11239-019-01973-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 7.7] [Reference Citation Analysis]
55 Peled H, Dau NQ, Lau H. Key Points to Consider When Evaluating Andexxa for Formulary Addition. Neurocrit Care 2020;33:20-4. [DOI: 10.1007/s12028-019-00866-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
56 Henze L, Sckell A, März A, Junghanß C. [Perioperative management of trauma surgery patients treated with direct oral anticoagulants]. Unfallchirurg 2019;122:633-45. [PMID: 31367841 DOI: 10.1007/s00113-019-0693-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
57 Rawal A, Ardeshna D, Minhas S, Cave B, Ibeguogu U, Khouzam R. Current status of oral anticoagulant reversal strategies: a review. Ann Transl Med 2019;7:411. [PMID: 31660310 DOI: 10.21037/atm.2019.07.101] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
58 Mtwesi V, Amit G. Stroke Prevention in Atrial Fibrillation: The Role of Oral Anticoagulation. Med Clin North Am 2019;103:847-62. [PMID: 31378330 DOI: 10.1016/j.mcna.2019.05.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
59 Smith MN, Deloney L, Carter C, Weant KA, Eriksson EA. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study. J Thromb Thrombolysis 2019;48:250-5. [DOI: 10.1007/s11239-019-01846-5] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 15.0] [Reference Citation Analysis]